That plus the longstanding safety profile (#msg-62332894) ensure that US Copaxone sales will never fall off a cliff, no matter how many of the oral MS drugs end up being approved in the next few years.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”